



		EMLc	ATC codes: L01BB02
Indication	Acute myeloid leukaemia with recurrent genetic abnormalities		
INN	Mercaptopurine		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Oral > Liquid: 20 mg per mL (EMLc) Oral > Solid: 50 mg tablet		
EML status history	First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents .		
Tags	Cancer		
Wikipedia	Mercaptopurine		
DrugBank	Mercaptopurine		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of mercaptopurine (oral liquid 20 mg/mL) to the EMLc.

